October 2014

Mesothelioma Eph-B4 Treatment Submitted to FDA for Phase I Clinical Trial

Malignant pleural mesothelioma often develops decades following exposure to asbestos. Currently, the best therapy produces a response in only half of the patients, and the median survival with the current therapy remains under a year. A search for novel targets and therapeutics is underway, and recently identified therapeutics includes Eph-B4.

The mesothelioma research lab at USC/Norris Comprehensive Cancer Center, where our donations go, has investigated the use of Eph-B4 in human mesothelioma tissues by immunohistochemistry. Xenograft tumors established with human mesothelioma cells were treated with an Eph-B4 inhibitor, as well as with a combinatorial effect of Eph-B4 and a biologic agent.

Eph-B4 was overexpressed, or shrunk the size of the tumor, in 72% of the mesothelioma tissues evaluated, with 85% of epithelioid and 38% of sarcomatoid subtypes demonstrating overexpression. The Eph-B4 inhibitor was highly active as a single agent to inhibit tumor growth and the combination of Ep-B4 and a biologic agent, Bevacizumab, was superior to each agent alone and led to complete tumor regression!

Mesothelioma Eph-B4 Treatment Phase I Clinical Trial

Since the study, Eph-B4 has been submitted to the FDA for Phase I Clinical Trials and is currently being offered to patients at the USC/Norris Comprehensive Cancer Center. Doctors from facilities such as, the University of Chicago , University of California , Davis , University of California , San Diego and Georgetown University , want to work with USC/Norris in treating more patients by offering their patients Eph-B4.

October 1, 2012

Dr. Parkash Gill of the USC Norris Comprehensive Cancer Center has announced that the new cancer fighting drug EPH-B4 has been submitted to the FDA for Phase I Clinical Trials and is available to qualifying mesothelioma patients. In the initial Phase I Trial EPH-B4 is available to newly diagnosed patients who have not undergone any conventional treatment options and to those patients who have exhausted all other treatment options such as surgery and chemotherapy. This is truly exciting as Dr. Gill has reported that EPH-B4 has shown great promise as a solo treatment or in conjunction with other drugs as Alimta, Cisplatin and Carboplatin.



Are you interested in trying a Clinical Trial?
Do you have questions related to malignant mesothelioma?

Dr. Gill and questions about mesothelioma treatment trials.
Dr. Parkash S. Gill is a professor of Medicine and Pathology and leads our trials team.


To answer these questions please use this form to send a request. Dr. Gill will make a reply by return e-mail.

Please allow some time for him to respond, depending on his schedule and the volume of questions this can take a few hours or days.

Compose your question for Dr. Gill here:

*required information

Contact Name:*
Email Address:*
Phone Number:*

Email Copy - Select to receive a copy of the submitted form.

To eliminate form spam and hijacking by automated bots we use Human Intelligence Identification. For your form to be submitted please answer the following question before you submit the form. The question MUST be answered in lower case.
What is the fifth letter of the alphabet?